on SGMO i couldn't find downgrade i found an upgrade on oct 30 October 30, 2008 07:28 EDT SGMO Sangamo BioSciences-SGMO's cash position is solid, says Cantor After Sangamo reported in-line EPS, Cantor Fitzgerald still expects the company to keep delivering positive clinical results, and they predict that Sangamo will enter a "substantial" clinical alliance. The firm maintained their Buy rating.
October 29, 2008 16:13 EDT SGMO theflyonthewall.com: Sangamo BioSciences-SGMO reports Q3 EPS (15c) vs. consensus of (16c) Reports Q3 revenue $3.75M vs. consensus of $3.98M. :theflyonthewall.com 07:27 EDT SGMO Sangamo BioSciences-SGMO's data shows the strength of its platform, says Cantor After Sangamo announced that it found that human T-cells can be made permanently resistant to HIV, Cantor Fitzgerald thinks the announcement shows the strength of the company's platform. The firm believes the shares are undervalued and they reiterated a Buy rating
Sort by:
Latest | Highest ratedBears Target McKesson [View article]
GS needs to hire u
Why I'm Buying Citigroup Stock [View article]
FDA Calendar Updates: ARDM, BFRM, CRTX, MDT, Zogenix [View instapost]
Big Pharma: Where's the Risk Management? [View article]
Citigroup Files to Increase Shares Outstanding to 60 Billion [View article]
Expect FDA Approval of AMAG Pharmaceutical's Feraheme [View article]
Lixte Biotech (OTC:LIXT): Key 2H09 Catalysts Await [View instapost]
Axcelis Technologies Hidden Value Play? [View instapost]
Biotech: The Next Big Bubble? [View article]
October 30, 2008
07:28 EDT SGMO
Sangamo BioSciences-SGMO's cash position is solid, says Cantor
After Sangamo reported in-line EPS, Cantor Fitzgerald still expects the company to keep delivering positive clinical results, and they predict that Sangamo will enter a "substantial" clinical alliance. The firm maintained their Buy rating.
October 29, 2008
16:13 EDT SGMO
theflyonthewall.com: Sangamo BioSciences-SGMO reports Q3 EPS (15c) vs. consensus of (16c)
Reports Q3 revenue $3.75M vs. consensus of $3.98M. :theflyonthewall.com
07:27 EDT SGMO
Sangamo BioSciences-SGMO's data shows the strength of its platform, says Cantor
After Sangamo announced that it found that human T-cells can be made permanently resistant to HIV, Cantor Fitzgerald thinks the announcement shows the strength of the company's platform. The firm believes the shares are undervalued and they reiterated a Buy rating
Rumors of Jamba Juice's Demise Greatly Overstated [View article]
Apple Credit Spreads: Targeting 500% Return [View article]
Apple Credit Spreads: Targeting 500% Return [View article]
Bloomberg's Premature Steve Jobs Obit: Why? [View article]
Parsing TiVo's Latest Conference Call [View article]
Solarfun Power Holdings: Expect a Rally from Key Support [View article]